Dr. Carlos Torres de Carvalho,
Director, Digestive Cancer Department and Medical Oncology Department
Champalimaud Cancer Center, Lisbon, Portugal
Dr. Carlos Carvalho is a Medical Oncologist based in Lisbon, where he serves as Director of both the Digestive Cancer Department and the Medical Oncology Department at the Champalimaud Cancer Center. With a career spanning clinical leadership, research and policy advising, Dr. Torres de Carvalho is a recognized authority in gastrointestinal and hepatobiliary cancers, as well as in rectal and pancreatic oncology.
He holds board certifications in Medical Oncology and Internal Medicine from the Portuguese Medical Boards. His international engagements include active roles in the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Group, and he contributes significantly to shaping national healthcare policy in Portugal.
He is a member of the Executive Direction of the Portuguese Medical Oncology Board, and a coordinating member of both the Portuguese National Program of Palliative Care and the Portuguese National Cancer Program. Additionally, he serves on the OECD Expert Group in Cancer Care, focused on quality improvement and survival outcomes.
Dr. Torres de Carvalho has published extensively in high-impact journals, with a particular focus on colorectal cancer, hepatic metastases, immunotherapy and chronotherapy. He has contributed to groundbreaking international trials, such as the OPTILIV trial and the International Watch & Wait Database (IWWD), and has been involved in translational research exploring biomarkers, immune response and precision oncology.
His more recent work includes leadership in studies on neoadjuvant strategies for rectal cancer, hepatic artery infusion chemotherapy, and organ-preservation approaches. He has also explored the clinical utility of zebrafish avatars, trained immunity and liquid biopsy markers for treatment monitoring and personalized care.
Dr. Torres de Carvalho is widely recognized for combining clinical excellence with research innovation, and for his commitment to advancing cancer care through multidisciplinary collaboration and patient-centered strategies.
